A sea change in EU data disclosure plans?
This article was originally published in SRA
Executive Summary
Is the European Medicines Agency really putting the brakes on its plans for wider public access to clinical trial data? It looks that way. After flying the flag of greater disclosure, and in the process bringing some major companies on board, it seems the wind has gone out of the agency's sails, deflated perhaps by strong headwinds from across the Atlantic1,2.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.